Daiichi Sankyō (4568.T) Financial Analysis & Valuation | Quarter Chart
Daiichi Sankyō (4568.T)
4568.TPrice: $16.86
Fair Value: 🔒
🔒score
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for... more
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells p... more
Description
Shares
| Market Cap | $30.68B | Exchange | JPX |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | JP | CEO | Hiroyuki Okuzawa |
| IPO Date | 2000-01-04 | CAGR | 0.05% |
| Employees | 18,726 | Website | www.daiichisankyo.com |
| Div. Yield | 2.94% | Payout Ratio | 0.42% |
| Buy Back Yield | 2.34% | Total Yield | 5.28% |
4568.T chart loading...
Fundamentals
Technicals
| Enterprise Value | $5956.45B | P/E Ratio | 18.84 |
| Forward P/E | — | PEG Ratio | -0.39 |
| P/S Ratio | 2.35 | P/B Ratio | 2.87 |
| P/CF Ratio | 39.59 | P/FCF Ratio | -458.94 |
| EPS | $0.94 | EPS Growth 1Y | 26.92% |
| EPS Growth 3Y | 428.47% | EPS Growth 5Y | 351.08% |
| Revenue Growth 1Y | 14.26% | Gross Margin | 0.78% |
| Operating Margin | 0.14% | Profit Margin | 0.15% |
| ROE | 0.19% | ROA | 0.08% |
| ROCE | 0.09% | Current Ratio | 2.69 |
| Quick Ratio | 1.85 | Cash Ratio | 0.7 |
| Debt/Equity | 0.18 | Interest Coverage | 24.8 |
| Altman Z Score | 3.15 | Piotroski Score | 6 |